ABSTRACT
Drugs used in conventional cytotoxic anticancer chemotherapy were created to cure cancer by either directly destroying or slowing the growth of cyclical tumor cells. The idea of using medications like angiogenesis inhibitors, however, has recently attracted a lot of attention. The reasoning is based on the fact that endothelial cell division occurs during the creation of new blood vessels, including tumor angiogenesis, and that almost all classes of cancer chemotherapy medications are created to damage DNA or disrupt the microtubules of dividing cells. According to the findings of recent experimental research, the repeated administration of specific cytotoxic treatments at low doses, a process known as “metronomic chemotherapy,” may improve the purported antiangiogenic effect of particular medications. Metronomic chemotherapy is the term used to describe the long-term administration of relatively small doses of cytotoxic medicines at brief, regular intervals, with no significant drug-free breaks. The benefit of this approach is less hazardous side effects and a lesser chance of drug-resistant tumor cells developing than with conventional delivery. In this review, the potential antiangiogenesis underpinnings of this therapeutic approach, as well as published experimental research and recent clinical studies investigating this less toxic schedule, are discussed.
